$ELVN News

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML Strategy

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70

JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75

Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73

Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82

Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78

Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate

Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67